Several preclinical studies have then followed to demonstrate the efficacy of anti-CD40 therapy in stimulating TAMs and resulting in tumor regression [215,216,217] and improvement of chemotherapy [218,219], anti-angiogenic therapy [217] and ICI [220,221] efficacies in different tumor models. This evidence concerns the gene CD40 and neoplasm.